About Time to Run: Autumn edition

Time to Run is an accessible running challenge everyone can take part in. You can take part, anywhere, anytime throughout November. You can run your 30 miles all in one go or spread your miles out to 1 mile a day – the choice is yours!

Whether you decide to run, jog, or walk, every mile you go will take us one step closer to finding a cure.

Take part in 5 easy steps:

1. Sign up now for free.

2. Your fundraising page will be automatically set up. Give it a personal touch and share it.

3. Join the Facebook group to hear updates on the challenge.

4. Start running your 30 miles on 1 November and track your progress with your fitness app or upload your miles manually.

5. Raise £150 and get your Time to Run T-shirt.

Your fundraising can help fund researchers such as Professor Michael Johnson and his research group at Imperial College London. Hear more about the work they’re doing to develop a potential new drug for Parkinson’s.

Through Parkinson’s UK’s drug accelerator grant scheme, Professor Michael Johnson’s research group has been awarded nearly £100,000 to develop a new drug for Parkinson’s. Using a method designed to improve the success of clinical trials, they’re using a computer-based programme to simulate what might make a good new drug to target.

Improving the success of clinical trials

Professor Johnson’s research group is one of the groups to benefit from the drug accelerator grant scheme. The grant provides funding for researchers to help bridge the gaps needed to progress their new drug. This helps push important research forward, bringing potential new drugs to people with Parkinson's sooner.

Lead researcher, Professor Michael Johnson, said:

“It is a great honour to be awarded this grant from Parkinson’s UK. A major problem with drug development is that half of all drugs will fail during clinical trials due to lack of efficacy - i.e. the drugs don’t work despite extensive testing prior to clinical trials in people.

“This award will fund us to develop a new type of drug as a potential treatment for Parkinson’s.”

Find out more about Parkinson’s UK’s research programme.